MedTrace Logo

Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB

NCT02819180 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2016-06-30

No results posted yet for this study

Summary

Prospective cohort study to evaluate the safety and immunogenicity of the Butantan Influenza vaccine (Fragmented and Inactivated) among healthy adults with 18 to 59 years of age and elderly older than 60 years of age.

Conditions

Interventions

BIOLOGICAL

Butantan Influenza Trivalent, Fragmented and Inactivated vaccine

Sponsors & Collaborators

  • Butantan Institute

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819180 on ClinicalTrials.gov